Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) CEO Eric M. Dube sold 21,125 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $243,360.00. Following the completion of the transaction, the chief executive officer now directly owns 361,975 shares of the company’s stock, valued at approximately $4,169,952. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Travere Therapeutics Stock Performance
Shares of TVTX opened at $12.86 on Tuesday. The company has a current ratio of 3.04, a quick ratio of 2.99 and a debt-to-equity ratio of 24.96. The firm’s fifty day simple moving average is $9.30 and its two-hundred day simple moving average is $7.86. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $14.62. The stock has a market capitalization of $979.02 million, a P/E ratio of -6.12 and a beta of 0.71.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.03). The business had revenue of $54.12 million for the quarter, compared to the consensus estimate of $49.50 million. Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%. As a group, analysts predict that Travere Therapeutics, Inc. will post -3.96 EPS for the current year.
Institutional Trading of Travere Therapeutics
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on the stock. HC Wainwright upped their price target on shares of Travere Therapeutics from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday. Bank of America upped their target price on Travere Therapeutics from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday. JPMorgan Chase & Co. lifted their price target on Travere Therapeutics from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Citigroup upped their price objective on Travere Therapeutics from $14.00 to $23.00 and gave the company a “buy” rating in a research note on Friday. Finally, Piper Sandler lifted their target price on shares of Travere Therapeutics from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.92.
Read Our Latest Stock Report on Travere Therapeutics
About Travere Therapeutics
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Further Reading
- Five stocks we like better than Travere Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- Why Block’s Key Components Make It a Solid Investment Choice
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.